[PDF][PDF] Recent advances in the development of immunostimulatory oligonucleotides

E Uhlmann, J Vollmer - Current Opinion in Drug Discovery and …, 2003 - researchgate.net
… power of the immune system by using synthetic oligonucleotides (… CpG ODNs for cancer
immunotherapy depends on the … development of suitable analytical methods for quality control. …

Immunotherapeutic uses of CpG oligodeoxynucleotides

DM Klinman - Nature Reviews Immunology, 2004 - nature.com
… of the innate immune system, and be of value in the immunotherapy of infectious disease, …
be required to assess the safety of repeated CpG stimulation of the innate immune system. …

Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides

G Mutwiri, LA Babiuk - Advanced drug delivery reviews, 2009 - Elsevier
… CpG oligodeoxynucleotides (ODN) activate the immune system and are promising
immunotherapeutic agents against infectious diseases, allergy/asthma and cancer. It has become …

Antisense and/or immunostimulatory oligonucleotide therapeutics

S Agrawal, ER Kandimalla - Current Cancer Drug Targets, 2001 - ingentaconnect.com
… ) as cellular immunotherapy, and v) to enhance response with … gene product and
simultaneously stimulate immune system to … oligos show activity at mg/kg doses and CpG oligos

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy

KD Wilson, SD de Jong, YK Tam - Advanced drug delivery reviews, 2009 - Elsevier
… largely to stimulate humoral immune responses which are … by the innate immune system
through interaction with the … our group has developed a method of encapsulation which relies on …

Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7

C Bourquin, L Schmidt, AL Lanz, B Storch… - The Journal of …, 2009 - journals.aai.org
… the efficacy of immunotherapeutic strategies against cancer … sequences that stimulate immune
responses through the … RNA oligonucleotides that activate a Th1-type immune response, …

The revival of CpG oligonucleotide-based cancer immunotherapies

T Adamus, M Kortylewski - Contemporary Oncology/Współczesna …, 2018 - termedia.pl
approaches using Tolllike Receptor 9 (TLR9) agonists, CpG oligodeoxynucleotides (ODNs),
focused on the generation of antitumor immune … blockade and immune stimulation leads to …

Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products

CA Nicolette, D Healey, I Tcherepanova, P Whelton… - Vaccine, 2007 - Elsevier
… cell immunotherapy has been shown to stimulate immune … active immune response, undefined
antigen approaches that … is used that involves oligonucleotide design to ensure removal …

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene …

JW Friedberg, H Kim, M McCauley, EM Hessel, P Sims… - Blood, 2005 - ashpublications.org
… this exciting combination immunotherapy approach to NHL. … have multiple effects on the
human immune system. ISSs signal … , several alternative approaches to stimulate effector-cell …

CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma

SA Miles, AD Sandler - Advanced drug delivery reviews, 2009 - Elsevier
… This approach enables biasing of host immunity toward a … the ability to stimulate the host
immune response and induce anti… of immune effector cells, their ability to stimulate an anti-tumor …